Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24626970 | 0.87 | DRD4 (0.32) | — | |
| SCHEMBL24171112 | 0.87 | DRD4 (0.32) | — | |
| SCHEMBL10204763 | 0.87 | DRD4 (0.32) | — | |
| SCHEMBL8259142 | 0.83 | — | — | |
| SCHEMBL14176504 | 0.83 | SAT1 (0.39) | — | |
| SCHEMBL12359990 | 0.83 | KCNH3 (0.34) | KCNH3CNR2DAOKDM1AMAOA | |
| SCHEMBL24762935 | 0.81 | CNR2 (0.30) | KCNH3CNR2 | |
| SCHEMBL24853530 | 0.80 | KDM1A (0.39) | DAOKDM1AMAOAMAOB | |
| SCHEMBL12376046 | 0.79 | PIK3CD (0.32) | — | |
| SCHEMBL11967194 | 0.78 | ADH1B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | KCNH3 3833/4885CNR2 1022/4885DAO 3603/4885 |
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KCNH3 4135/4885CNR2 1909/4885DAO 4490/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KCNH3 3669/4885CNR2 1055/4885DAO 2757/4885 |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | KCNH3 1323/4885CNR2 4476/4885DAO 3281/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | KCNH3 3350/4885CNR2 757/4885DAO 1007/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | KCNH3 3833/4885CNR2 1022/4885DAO 3603/4885 |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | PDE4A, PDE3B, PDE4B | KCNH3 535/4885CNR2 536/4885DAO 1113/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | KCNH3 2665/4885CNR2 3320/4885DAO 3859/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KCNH3 3833/4885CNR2 1022/4885DAO 3603/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | KCNH3 4759/4885CNR2 1570/4885DAO 4175/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | KCNH3 4135/4885CNR2 1909/4885DAO 4490/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | KCNH3 4720/4885CNR2 4247/4885DAO 3149/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | KCNH3 2989/4885CNR2 22/4885DAO 2903/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | KCNH3 3434/4885CNR2 4830/4885DAO 1947/4885 |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KCNH3 3833/4885CNR2 1022/4885DAO 3603/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KCNH3 3538/4885CNR2 1813/4885DAO 4027/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | KCNH3 4105/4885CNR2 3812/4885DAO 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.